| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Carcinoma, Non-Small-Cell Lung | 19 | 2021 | 896 | 4.58 | Why? |
| Lung Neoplasms | 28 | 2021 | 3228 | 3.24 | Why? |
| Small Cell Lung Carcinoma | 3 | 2021 | 133 | 2.14 | Why? |
| Pneumonectomy | 2 | 2021 | 278 | 0.85 | Why? |
| Thoracic Neoplasms | 5 | 2020 | 343 | 0.72 | Why? |
| Medical Oncology | 10 | 2021 | 3826 | 0.71 | Why? |
| Antineoplastic Agents | 8 | 2021 | 3550 | 0.66 | Why? |
| Central Nervous System Neoplasms | 1 | 2017 | 88 | 0.66 | Why? |
| Immunotherapy | 7 | 2019 | 2421 | 0.65 | Why? |
| Carbazoles | 1 | 2017 | 120 | 0.63 | Why? |
| Radiotherapy | 2 | 2021 | 608 | 0.62 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 1573 | 0.57 | Why? |
| Drug Resistance, Neoplasm | 1 | 2018 | 447 | 0.55 | Why? |
| Neoplasm Staging | 8 | 2020 | 1999 | 0.54 | Why? |
| Antineoplastic Agents, Immunological | 2 | 2019 | 830 | 0.53 | Why? |
| Neoplasms | 14 | 2021 | 17251 | 0.52 | Why? |
| B7-H1 Antigen | 4 | 2019 | 541 | 0.45 | Why? |
| Pyridines | 1 | 2017 | 680 | 0.44 | Why? |
| Piperidines | 1 | 2017 | 795 | 0.43 | Why? |
| Protein Kinase Inhibitors | 2 | 2018 | 1585 | 0.42 | Why? |
| Carcinoma, Squamous Cell | 2 | 2018 | 902 | 0.37 | Why? |
| Oncogene Proteins, Fusion | 2 | 2018 | 52 | 0.36 | Why? |
| Oncology Nursing | 2 | 2021 | 156 | 0.34 | Why? |
| Pyrazoles | 1 | 2017 | 1791 | 0.32 | Why? |
| Advanced Practice Nursing | 2 | 2018 | 106 | 0.32 | Why? |
| Antibodies, Monoclonal | 4 | 2019 | 8041 | 0.32 | Why? |
| Receptor Protein-Tyrosine Kinases | 2 | 2018 | 243 | 0.31 | Why? |
| Information Dissemination | 1 | 2021 | 2986 | 0.29 | Why? |
| Programmed Cell Death 1 Receptor | 2 | 2018 | 724 | 0.25 | Why? |
| Immunologic Factors | 1 | 2018 | 4206 | 0.24 | Why? |
| Antibodies, Monoclonal, Humanized | 3 | 2018 | 9335 | 0.23 | Why? |
| Clinical Decision-Making | 5 | 2021 | 3755 | 0.22 | Why? |
| Erlotinib Hydrochloride | 2 | 2017 | 48 | 0.21 | Why? |
| Oncologists | 3 | 2021 | 877 | 0.20 | Why? |
| Global Burden of Disease | 2 | 2020 | 531 | 0.20 | Why? |
| Ipilimumab | 1 | 2019 | 102 | 0.19 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 2 | 2020 | 1261 | 0.19 | Why? |
| Social Media | 1 | 2021 | 5798 | 0.19 | Why? |
| Acetanilides | 1 | 2018 | 9 | 0.19 | Why? |
| PTEN Phosphohydrolase | 1 | 2018 | 70 | 0.18 | Why? |
| Intention to Treat Analysis | 2 | 2017 | 673 | 0.18 | Why? |
| RANK Ligand | 1 | 2017 | 47 | 0.18 | Why? |
| Retreatment | 1 | 2018 | 186 | 0.18 | Why? |
| Proto-Oncogene Proteins c-met | 1 | 2017 | 40 | 0.17 | Why? |
| Chemoradiotherapy | 1 | 2020 | 362 | 0.17 | Why? |
| Gene Amplification | 1 | 2017 | 85 | 0.17 | Why? |
| Taxoids | 1 | 2016 | 45 | 0.17 | Why? |
| Radiosurgery | 1 | 2020 | 249 | 0.17 | Why? |
| Platinum | 1 | 2016 | 54 | 0.17 | Why? |
| Pathologists | 1 | 2018 | 168 | 0.16 | Why? |
| Registries | 4 | 2020 | 12327 | 0.16 | Why? |
| AIDS Serodiagnosis | 1 | 2017 | 64 | 0.16 | Why? |
| Delivery of Health Care | 2 | 2020 | 15909 | 0.16 | Why? |
| Influenza, Human | 1 | 2021 | 10779 | 0.16 | Why? |
| Humans | 50 | 2021 | 930598 | 0.15 | Why? |
| Epithelial-Mesenchymal Transition | 1 | 2018 | 242 | 0.15 | Why? |
| Genetic Engineering | 1 | 2017 | 325 | 0.15 | Why? |
| Neoplasm Metastasis | 1 | 2019 | 682 | 0.15 | Why? |
| Heterocyclic Compounds, 3-Ring | 1 | 2018 | 275 | 0.15 | Why? |
| Disease-Free Survival | 2 | 2017 | 1654 | 0.14 | Why? |
| ErbB Receptors | 1 | 2017 | 320 | 0.14 | Why? |
| Drug Utilization | 1 | 2020 | 619 | 0.14 | Why? |
| Practice Guidelines as Topic | 5 | 2021 | 15421 | 0.13 | Why? |
| Follow-Up Studies | 5 | 2021 | 17020 | 0.13 | Why? |
| Diagnosis, Computer-Assisted | 1 | 2018 | 436 | 0.13 | Why? |
| Pneumonia, Viral | 12 | 2020 | 243684 | 0.13 | Why? |
| Telemedicine | 3 | 2021 | 25032 | 0.13 | Why? |
| Coronavirus Infections | 12 | 2020 | 253789 | 0.12 | Why? |
| Standard of Care | 1 | 2020 | 1297 | 0.12 | Why? |
| Infusions, Intravenous | 1 | 2017 | 1224 | 0.12 | Why? |
| Switzerland | 5 | 2019 | 2738 | 0.12 | Why? |
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 1014 | 0.12 | Why? |
| Surgical Oncology | 1 | 2020 | 923 | 0.12 | Why? |
| Radiation Oncology | 1 | 2020 | 834 | 0.12 | Why? |
| Combined Modality Therapy | 2 | 2019 | 3395 | 0.11 | Why? |
| Brain Neoplasms | 1 | 2019 | 669 | 0.11 | Why? |
| Netherlands | 1 | 2021 | 3533 | 0.11 | Why? |
| Betacoronavirus | 12 | 2020 | 204454 | 0.11 | Why? |
| Fluorodeoxyglucose F18 | 1 | 2019 | 1153 | 0.11 | Why? |
| Patient Reported Outcome Measures | 1 | 2017 | 912 | 0.11 | Why? |
| Mutation | 4 | 2019 | 12376 | 0.11 | Why? |
| Self Efficacy | 1 | 2017 | 717 | 0.11 | Why? |
| Immunohistochemistry | 1 | 2018 | 2275 | 0.11 | Why? |
| Neoplasm Recurrence, Local | 1 | 2018 | 1063 | 0.11 | Why? |
| Nurse's Role | 1 | 2018 | 614 | 0.10 | Why? |
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 3633 | 0.10 | Why? |
| International Cooperation | 5 | 2020 | 3436 | 0.10 | Why? |
| Mass Screening | 3 | 2019 | 8005 | 0.09 | Why? |
| Patient Care Management | 1 | 2020 | 1514 | 0.09 | Why? |
| Pandemics | 17 | 2021 | 389249 | 0.09 | Why? |
| Patient Acceptance of Health Care | 2 | 2017 | 5002 | 0.09 | Why? |
| Kaplan-Meier Estimate | 1 | 2017 | 4260 | 0.09 | Why? |
| HIV Infections | 3 | 2018 | 11620 | 0.08 | Why? |
| Male | 22 | 2020 | 367725 | 0.08 | Why? |
| Gene Expression | 1 | 2017 | 3332 | 0.08 | Why? |
| Female | 22 | 2020 | 380317 | 0.08 | Why? |
| Prognosis | 6 | 2020 | 32490 | 0.08 | Why? |
| Genomics | 1 | 2018 | 3118 | 0.08 | Why? |
| Survival Rate | 2 | 2018 | 9206 | 0.07 | Why? |
| Aged | 15 | 2020 | 215776 | 0.07 | Why? |
| Middle Aged | 16 | 2020 | 270681 | 0.07 | Why? |
| Outpatients | 1 | 2017 | 3417 | 0.07 | Why? |
| Cohort Studies | 5 | 2021 | 36005 | 0.07 | Why? |
| Genetic Variation | 1 | 2018 | 3919 | 0.07 | Why? |
| Drug Discovery | 1 | 2018 | 3092 | 0.07 | Why? |
| Mortality | 1 | 2021 | 7132 | 0.07 | Why? |
| Time-to-Treatment | 1 | 2020 | 5883 | 0.06 | Why? |
| Attitude of Health Personnel | 2 | 2018 | 4741 | 0.06 | Why? |
| Intersectoral Collaboration | 2 | 2020 | 1065 | 0.06 | Why? |
| Venous Thromboembolism | 1 | 2021 | 4273 | 0.06 | Why? |
| Ambulatory Care | 1 | 2020 | 4947 | 0.06 | Why? |
| Practice Patterns, Physicians' | 2 | 2020 | 4927 | 0.06 | Why? |
| Healthcare Disparities | 1 | 2020 | 3893 | 0.06 | Why? |
| Aged, 80 and over | 5 | 2019 | 88759 | 0.06 | Why? |
| Adult | 12 | 2020 | 244371 | 0.06 | Why? |
| Infection Control | 2 | 2020 | 23131 | 0.05 | Why? |
| Referral and Consultation | 1 | 2017 | 4816 | 0.05 | Why? |
| Risk Factors | 5 | 2021 | 71621 | 0.05 | Why? |
| Triage | 1 | 2020 | 7151 | 0.05 | Why? |
| Emergency Medical Services | 1 | 2017 | 3557 | 0.05 | Why? |
| Epidemics | 1 | 2021 | 6407 | 0.05 | Why? |
| United Kingdom | 1 | 2021 | 18046 | 0.05 | Why? |
| Immunosuppressive Agents | 1 | 2019 | 6331 | 0.05 | Why? |
| Disease Management | 1 | 2018 | 6841 | 0.05 | Why? |
| Biomarkers, Tumor | 2 | 2019 | 1314 | 0.05 | Why? |
| Genetic Heterogeneity | 1 | 2019 | 77 | 0.05 | Why? |
| Carcinoma, Large Cell | 1 | 2018 | 13 | 0.05 | Why? |
| United States | 3 | 2021 | 46150 | 0.05 | Why? |
| Disease Progression | 1 | 2018 | 13580 | 0.05 | Why? |
| Tissue Array Analysis | 1 | 2018 | 75 | 0.05 | Why? |
| Maximum Tolerated Dose | 1 | 2018 | 65 | 0.05 | Why? |
| Response Evaluation Criteria in Solid Tumors | 1 | 2017 | 37 | 0.04 | Why? |
| Tumor Burden | 1 | 2019 | 369 | 0.04 | Why? |
| Gene Dosage | 1 | 2017 | 101 | 0.04 | Why? |
| Artifacts | 1 | 2019 | 250 | 0.04 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2017 | 13720 | 0.04 | Why? |
| Global Health | 1 | 2021 | 13911 | 0.04 | Why? |
| Nurse Clinicians | 1 | 2018 | 92 | 0.04 | Why? |
| Exons | 1 | 2017 | 158 | 0.04 | Why? |
| Necrosis | 1 | 2019 | 532 | 0.04 | Why? |
| Crowdsourcing | 1 | 2020 | 258 | 0.04 | Why? |
| Drug Therapy | 1 | 2019 | 280 | 0.04 | Why? |
| Italy | 1 | 2021 | 38444 | 0.04 | Why? |
| HIV Seropositivity | 1 | 2018 | 320 | 0.04 | Why? |
| Cause of Death | 2 | 2020 | 4823 | 0.04 | Why? |
| Bevacizumab | 1 | 2017 | 149 | 0.04 | Why? |
| Severity of Illness Index | 2 | 2021 | 48226 | 0.04 | Why? |
| Public Health | 1 | 2021 | 16359 | 0.04 | Why? |
| Treatment Outcome | 2 | 2020 | 51732 | 0.04 | Why? |
| Proof of Concept Study | 1 | 2017 | 696 | 0.03 | Why? |
| Focus Groups | 1 | 2018 | 811 | 0.03 | Why? |
| Emergency Service, Hospital | 2 | 2017 | 14232 | 0.03 | Why? |
| Databases, Factual | 2 | 2020 | 6248 | 0.03 | Why? |
| Immunotherapy, Adoptive | 1 | 2019 | 524 | 0.03 | Why? |
| China | 1 | 2021 | 50654 | 0.03 | Why? |
| Asia | 1 | 2020 | 2399 | 0.03 | Why? |
| Tomography, X-Ray Computed | 1 | 2020 | 25144 | 0.03 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 8811 | 0.03 | Why? |
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 1316 | 0.03 | Why? |
| Interdisciplinary Communication | 1 | 2020 | 1425 | 0.03 | Why? |
| Europe | 2 | 2020 | 12702 | 0.03 | Why? |
| Young Adult | 3 | 2018 | 93724 | 0.03 | Why? |
| Telephone | 1 | 2021 | 1705 | 0.03 | Why? |
| Neuroimaging | 1 | 2019 | 1106 | 0.03 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.03 | Why? |
| Surveys and Questionnaires | 4 | 2020 | 43792 | 0.03 | Why? |
| Animals | 2 | 2017 | 78931 | 0.03 | Why? |
| Professional-Patient Relations | 1 | 2015 | 426 | 0.03 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.03 | Why? |
| History, 21st Century | 1 | 2017 | 1849 | 0.02 | Why? |
| Quality of Life | 2 | 2021 | 9820 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2018 | 3776 | 0.02 | Why? |
| Precision Medicine | 1 | 2019 | 1477 | 0.02 | Why? |
| Early Diagnosis | 1 | 2017 | 2443 | 0.02 | Why? |
| Continuity of Patient Care | 1 | 2018 | 1574 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2021 | 3228 | 0.02 | Why? |
| Feasibility Studies | 1 | 2017 | 3467 | 0.02 | Why? |
| Hospitals, Teaching | 1 | 2015 | 1609 | 0.02 | Why? |
| Australia | 1 | 2020 | 6306 | 0.02 | Why? |
| Canada | 1 | 2020 | 6018 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2020 | 7268 | 0.02 | Why? |
| Hydroxychloroquine | 2 | 2020 | 12447 | 0.02 | Why? |
| Cross-Sectional Studies | 3 | 2020 | 53120 | 0.02 | Why? |
| Qualitative Research | 1 | 2018 | 4337 | 0.02 | Why? |
| Survival Analysis | 1 | 2019 | 7592 | 0.02 | Why? |
| Hospitals, University | 1 | 2018 | 4173 | 0.02 | Why? |
| Comorbidity | 2 | 2020 | 34796 | 0.02 | Why? |
| Azithromycin | 1 | 2020 | 3943 | 0.02 | Why? |
| Academic Medical Centers | 1 | 2017 | 3088 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2020 | 9893 | 0.02 | Why? |
| Consensus | 1 | 2019 | 6345 | 0.02 | Why? |
| Glucocorticoids | 1 | 2020 | 4431 | 0.02 | Why? |
| Computer Simulation | 1 | 2019 | 4982 | 0.02 | Why? |
| Sex Factors | 1 | 2020 | 11014 | 0.02 | Why? |
| Adenosine Monophosphate | 1 | 2020 | 5652 | 0.02 | Why? |
| Alanine | 1 | 2020 | 5687 | 0.02 | Why? |
| Retrospective Studies | 3 | 2019 | 105322 | 0.01 | Why? |
| Spain | 1 | 2020 | 15545 | 0.01 | Why? |
| Algorithms | 1 | 2019 | 7346 | 0.01 | Why? |
| Serologic Tests | 1 | 2015 | 4359 | 0.01 | Why? |
| Drug Repositioning | 1 | 2020 | 5683 | 0.01 | Why? |
| Signal Transduction | 1 | 2017 | 7207 | 0.01 | Why? |
| Breast Neoplasms | 1 | 2019 | 3633 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2017 | 10998 | 0.01 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.01 | Why? |
| Mice | 1 | 2017 | 21357 | 0.01 | Why? |
| Communication | 1 | 2015 | 5206 | 0.01 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.01 | Why? |
| Risk Assessment | 1 | 2021 | 25439 | 0.01 | Why? |
| Hospital Mortality | 1 | 2020 | 22087 | 0.01 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.01 | Why? |
| Prevalence | 1 | 2017 | 25773 | 0.01 | Why? |
| Prospective Studies | 1 | 2017 | 43301 | 0.01 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.01 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.01 | Why? |
| Adolescent | 1 | 2015 | 86841 | 0.00 | Why? |